The anal fissure treatment market size is expected to see strong growth in the next few years. It will grow to $2.01 billion in 2028 at a compound annual growth rate (CAGR) of 9.1%. The anticipated growth in the forecast period can be attributed to several factors, including the introduction of innovative treatment approaches for anal fissures, an increase in the incidence rates of such conditions, investments in research and development activities, a shift towards patient-centric care models, and changes in healthcare policies. Key trends expected in the forecast period encompass technological advancements in anal fissure treatments, a growing demand for minimally invasive procedures, a rise in the incidence of anal fissures, a focus on patient-centric approaches to care, and trends related to globalization and market expansion in the healthcare sector.
The burgeoning elderly demographic coupled with unhealthy lifestyle trends is anticipated to act as a driving force for the anal fissure treatment market. As per the World Health Organization (WHO) report in October 2022, it's projected that by 2030, one in six individuals globally will be 60 years or older, rising to a staggering 2.1 billion by 2050. This shift, primarily attributed to age-related factors and detrimental health habits, is foreseen to necessitate increased treatment for anal fissures caused by internal sphincter thinning and tearing.
The escalating incidence of gastrointestinal disorders is poised to significantly contribute to the expansion of the anal fissure treatment market. Gastrointestinal disorders affecting the gastrointestinal (GI) tract are expected to see a concurrent rise in anal fissure occurrences, stimulating demand for specialized treatments. For instance, projections from a May 2021 report by BioMed Central suggest a substantial surge in Inflammatory Bowel Disease (IBD) cases by 2035 across various regions. This surge includes a 2.5-fold rise in Iran, reaching 69 thousand cases, and significant increases in prevalence across North Africa, the Middle East, India, East Asia, high-income Asia-Pacific, and Southeast Asia regions.
The upward trajectory in constipation rates is forecasted to be a driving force behind the growth of the anal fissure treatment market. Constipation, characterized by difficulty passing stools and infrequent bowel movements, often leads to anal fissures due to anus lining damage, necessitating treatment. According to the National Library of Medicine's 2021 data, the global prevalence of constipation was between 12% and 19%, with an estimated annual expenditure of around $7 billion allocated for constipation testing. This escalating prevalence underscores the demand for anal fissure treatments prompted by the increasing constipation rate.
Prominent entities within the anal fissure treatment market are actively innovating by introducing topical treatments specifically tailored to cater to a larger customer base, drive sales, and bolster revenue streams. Anal fissure topical treatments encompass medicinal applications or ointments directly administered to the affected anal fissure area. Notably, in July 2023, Acrux Limited, a pharmaceutical firm based in Australia, announced the initiation of the United States Food and Drug Administration (FDA) review process for Nitroglycerin Ointment, 0.4%. This product's distinctive feature lies in its efficacy in alleviating moderate to severe pain associated with chronic anal fissures, targeting discomfort stemming from the tear in the anus lining. Acrux Limited focuses on advancing advanced-stage projects set for imminent commercialization while simultaneously making significant strides in the development of earlier-stage products, ensuring a diverse and robust product pipeline.
In July 2021, AstraZeneca Plc., a UK-based pharmaceutical and biotechnology enterprise primarily engaged in prescription medicine development and commercialization, successfully completed the acquisition of Alexion Pharmaceuticals Inc. for an undisclosed sum. This strategic acquisition aims to amalgamate resources, leveraging Alexion's expertise, to facilitate AstraZeneca's expansion into rare disease medications and advance their research and development initiatives in pharmaceutical discoveries. Alexion Pharmaceuticals Inc., a US-based biopharmaceutical company renowned for its focus on pioneering life-altering therapies, becomes an integral part of AstraZeneca's journey toward novel medical solutions.
Major companies operating in the anal fissure treatment market report are SRS Life Sciences Inc., Healthy Life Pharma Private Limited, Eisai Co. Ltd., AstraZeneca plc, Bayer AG, Novasep Holding S.A.S., Geri-care Pharmaceuticals Corp., Abbott Laboratories, GlaxoSmithKline plc, Valeant Pharmaceuticals International Inc., Taro Pharmaceutical Industries Ltd., Cook Pharmica LLC, Pfizer Inc., Taj Pharmaceuticals Limited, Troikaa Pharmaceuticals Ltd., Purdue Pharma LP, Allergan Inc., SRS Pharmaceuticals, Ultragenyx Pharmaceutical Inc., BioMarin Pharmaceutical Inc., Enobia Pharma Corporation, Alexion Pharmaceuticals Inc., Regeneron Pharmaceuticals Inc., Jazz Pharmaceuticals plc, Mallinckrodt Pharmaceuticals Limited, Sanofi S.A., Eli Lilly and Company, Roche Holding AG, Johnson & Johnson Services Inc., AbbVie Inc., Amgen Inc., Biogen Inc., Bristol-Myers Squibb Company, Celgene Corporation, Gilead Sciences Inc.
North America was the largest region in the anal fissure treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the anal fissure treatment market report during the forecast period. The regions covered in the anal fissure treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the anal fissure treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The primary types of anal fissure treatments include topical nitroglycerin, calcium channel blockers, stool softeners, and others. Topical nitroglycerin is an ointment specifically employed for the treatment of chronic anal fissures, effectively reducing moderate to severe discomfort. This medication belongs to the nitrate drug family. The major routes of administration for these treatments include topical and oral methods, and they find application in various healthcare settings such as clinics, hospitals, and others.
The anal fissure treatment market research report is one of a series of new reports that provides anal fissure treatment market statistics, including anal fissure treatment industry global market size, regional shares, competitors with a anal fissure treatment market share, detailed anal fissure treatment market segments, market trends and opportunities, and any further data you may need to thrive in the anal fissure treatment industry. This anal fissure treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
Executive Summary
Anal Fissure Treatment Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on anal fissure treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
- Assess the Russia-Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for anal fissure treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type: Topical Nitroglycerin; Calcium Channel Blockers; Stool Softeners; Other Types
2) By Route of Administration: Topical; Oral
3) By Application: Clinics; Hospitals; Other Applications
Companies Mentioned: SRS Life Sciences Inc.; Healthy Life Pharma Private Limited; Eisai Co. Ltd.; AstraZeneca plc; Bayer AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- SRS Life Sciences Inc.
- Healthy Life Pharma Private Limited
- Eisai Co. Ltd.
- AstraZeneca plc
- Bayer AG
- Novasep Holding S.A.S.
- Geri-care Pharmaceuticals Corp.
- Abbott Laboratories
- GlaxoSmithKline plc
- Valeant Pharmaceuticals International Inc.
- Taro Pharmaceutical Industries Ltd.
- Cook Pharmica LLC
- Pfizer Inc.
- Taj Pharmaceuticals Limited
- Troikaa Pharmaceuticals Ltd.
- Purdue Pharma LP
- Allergan Inc.
- SRS Pharmaceuticals
- Ultragenyx Pharmaceutical Inc.
- BioMarin Pharmaceutical Inc.
- Enobia Pharma Corporation
- Alexion Pharmaceuticals Inc.
- Regeneron Pharmaceuticals Inc.
- Jazz Pharmaceuticals plc
- Mallinckrodt Pharmaceuticals Limited
- Sanofi S.A.
- Eli Lilly and Company
- Roche Holding AG
- Johnson & Johnson Services Inc.
- AbbVie Inc.
- Amgen Inc.
- Biogen Inc.
- Bristol-Myers Squibb Company
- Celgene Corporation
- Gilead Sciences Inc.
Methodology
LOADING...